Marksans Pharma Q4FY26: Revenue ₹856 cr, PAT ₹149 cr

What stood out in the March 2026 quarter

Marksans Pharma reported a strong set of earnings for the March 2026 quarter (Q4FY26), led by higher revenue and a sharp improvement in operating profitability. Consolidated revenue from operations rose to ₹856.11 crore, up from ₹708.46 crore in the same quarter last year (Q4FY25). The company also reported a rise in total income to ₹891.29 crore from ₹723.80 crore a year ago.

The quarter was marked by a visible shift in operating leverage. EBITDA increased to ₹195.42 crore from ₹126.94 crore in Q4FY25, and the EBITDA margin expanded to 22.8% from 17.9%. Profit after tax (PAT) came in at ₹149.03 crore, compared with ₹90.73 crore in the year-ago quarter.

Revenue performance: higher base across the quarter

The topline improvement in Q4FY26 was broad-based as per the consolidated headline numbers shared. Revenue from operations increased by about ₹147.65 crore year-on-year, moving from ₹708.46 crore to ₹856.11 crore. Total income also increased by about ₹167.49 crore year-on-year to ₹891.29 crore.

While the provided data does not break Q4FY26 revenue by region, it does offer context from prior reported periods. In Q4FY25, Marksans Pharma had disclosed revenue from the U.S. and North America at ₹328.6 crore and revenue from the U.K. and EU formulation business at ₹274.1 crore. That earlier quarter also recorded “rest of the world” revenue of ₹29.3 crore.

Operating profitability: EBITDA jumps, margin expands

The most significant change in Q4FY26 was in operating profitability. EBITDA rose to ₹195.42 crore from ₹126.94 crore in Q4FY25. The EBITDA margin increased to 22.8% from 17.9%, showing a sharp improvement in cost efficiency versus the previous year’s quarter.

The company attributed the quarterly performance to continued momentum in the formulations business, improved operating leverage, and margin expansion. In addition, the company reported total comprehensive income of ₹202.97 crore in Q4FY26 versus ₹117.21 crore in Q4FY25, aided by foreign currency translation gains.

Profit line: PAT and PBT both rise strongly

PAT for Q4FY26 was ₹149.03 crore, up from ₹90.73 crore in Q4FY25. Profit before tax (PBT) was reported at ₹200 crore for Q4FY26, significantly higher than ₹116.09 crore in the year-ago quarter.

The data also indicates that the company’s profitability improved within the year, not just versus last year. That sequential improvement is important because it shows momentum through the second half of FY26, at least as reflected in the reported quarterly comparison.

Sequential trends: Q4FY26 improved over Q3FY26

Marksans Pharma reported sequential growth in both revenue and PAT in Q4FY26 compared with Q3FY26. Revenue from operations increased to ₹856.11 crore from ₹754.43 crore. PAT rose to ₹149.03 crore from ₹113.69 crore.

This sequential rise coincided with stronger operating performance and a higher EBITDA margin in Q4FY26. The provided information does not specify one-off items in Q4FY26 beyond foreign currency translation gains contributing to comprehensive income, so the operating margin expansion remains the key reported driver.

Key numbers snapshot: Q4FY26 vs Q4FY25 vs Q3FY26

FY25 context: record year, but mixed margin commentary

Alongside the Q4FY26 print, the provided information includes a separate FY25 performance summary. For the full year FY25, Marksans Pharma reported revenue of ₹2,623 crore, and net profit growth of 21.5% year-on-year. The company also stated that FY25 was its highest-ever revenue and profit year, with operating revenue and profit after tax both rising about 21% year-on-year.

In FY25, EBITDA was reported at ₹528.6 crore with an EBITDA margin of 20.2%. EPS for FY25 rose to ₹8.4 from ₹6.9 in FY24. Gross margin improved by 407 basis points year-on-year to 56.4%, attributed to a better product mix and lower raw material prices. However, FY25 commentary also noted that EBITDA margin dipped slightly versus the prior year due to higher employee costs, R&D, and freight costs.

FY24 as a reference point: growth and cash metrics disclosed earlier

The article text also includes FY24 disclosures for Marksans Pharma. For FY24, revenue was reported at ₹2,177.4 crore, EBITDA at ₹459 crore, and PAT at ₹314.9 crore. EPS for FY24 was ₹6.92. The same FY24 summary included cash flow and balance sheet metrics such as cash from operations of ₹230 crore, free cash flow of ₹21.6 crore, capex of ₹208 crore, R&D spend of ₹34.6 crore (1.6% of sales), and cash reserves of ₹674 crore as of March 31, 2024. A dividend of ₹0.6 per equity share was also mentioned.

Market impact and what investors typically track next

The provided Q4FY26 information is primarily financial, and it does not include a stated share price reaction for this specific quarter. However, earlier context shows that following a weak set of March quarter results in Q4FY24, Marksans Pharma shares fell as much as 12.93% intraday to ₹147.45 per share, with the stock trading at ₹153.25 per share at 1:12 PM that day.

For Q4FY26, the key markers for investors based on the numbers provided are the jump in EBITDA and the higher EBITDA margin, the rise in PAT, and the sequential improvement from Q3FY26. The mention of foreign currency translation gains also indicates that currency movement affected comprehensive income during the quarter.

Conclusion

Marksans Pharma’s Q4FY26 results show higher revenue, a sharp improvement in EBITDA, and strong growth in PAT versus both last year and the previous quarter. The company linked performance to formulations momentum, operating leverage, and margin expansion, with comprehensive income also supported by foreign currency translation gains.